A Real Consultation Experience of a Couple Who Are Genetic Carriers
A young couple came to the clinic: the husband was 35, the wife 32. The husband had a family history of spinal muscular atrophy (SMA) and was a carrier; after screening, the wife was also confirmed to be a carrier. Their naturally conceived children had a 25% chance of being affected and a 50% chance of being carriers. They did not want to take the risk, nor did they want to experience a mid-term pregnancy termination. After completing genetic counseling, they took all their domestic test reports, including both partners' genetic test results, chromosome karyotype analysis, AMH, and semen analysis, and went to Kyrgyzstan to start a third-generation IVF cycle. This case is not an isolated one; in the past two years, the number of consultations for similar situations has increased significantly in reproductive genetics clinics.
Going to Kyrgyzstan for Third-Generation IVF with Genetic Disease: Direct Answer
For couples with a family history of genetic disease or who clearly carry pathogenic genes and want a healthy baby, going to Kyrgyzstan for third-generation IVF (PGT, Preimplantation Genetic Testing) is technically feasible. Some fertility centers in Kyrgyzstan have the capability for PGT-M (monogenic disease testing) and PGT-SR (chromosomal structural rearrangement testing), allowing them to screen embryos for pathogenic genes and select embryos that do not carry the disease for transfer. However, the success of obtaining a healthy embryo depends on the type of pathogenic gene, whether the mutation site is clear, the woman's ovarian reserve, embryo developmental potential, and the laboratory testing technology platform.
When is it suitable to go to Kyrgyzstan for PGT?
- Clearly carrying pathogenic genes for autosomal dominant, recessive, or X-linked genetic diseases, with the mutation site confirmed by genetic testing.
- Both partners are carriers of the same recessive genetic disease, such as SMA, thalassemia, deafness genes, etc.
- Carriers of structural rearrangements such as balanced translocation or Robertsonian translocation, requiring screening for embryos with normal chromosome copy number.
- Previous history of giving birth to a child with a genetic disease or multiple pregnancy terminations due to fetal genetic abnormalities.
- The woman has adequate ovarian reserve (AMH ≥ 1.0 ng/mL, antral follicle count ≥ 6), allowing for retrieval of a sufficient number of oocytes for embryo culture and biopsy.
When is it not suitable?
- The pathogenic gene is not identified, or an effective testing probe cannot be established for the family; PGT-M cannot be performed.
- The woman has severely diminished ovarian reserve (AMH < 0.5 ng/mL), with a very low expected number of retrieved eggs and a high risk of having no transferable embryos after biopsy.
- The genetic disease carried by both partners is polygenic or mitochondrial; current PGT technology cannot effectively screen for these.
- The man has azoospermia and sperm cannot be obtained surgically, or sperm quality is extremely poor, preventing the formation of embryos suitable for biopsy.
- The local laboratory in Kyrgyzstan does not have the necessary conditions for testing the specific genetic disease (e.g., some rare mutations require custom probes that cannot be made locally).
Why Do Couples with Genetic Diseases Choose to Go to Kyrgyzstan?
Domestically, third-generation IVF is strictly regulated by policy, requiring clear medical indications, and the openness to carrier screening varies among centers. Kyrgyzstan has relatively liberal assisted reproductive legislation, with fewer restrictions on PGT indications. As long as both parties provide genetic test reports and genetic counseling records, they can enter the cycle. Additionally, the overall cost of third-generation IVF in Kyrgyzstan is about 50% to 60% of that in China, with shorter cycle waiting times and no need for lengthy ethical approval queues. This does not mean Kyrgyzstan is better than China, but it offers an alternative path, especially for genetic carrier couples who cannot immediately start a cycle in China due to policy reasons.
How Do Doctors View Going to Kyrgyzstan for PGT?
As a reproductive physician, my core concerns are: whether the genetic diagnosis is clear, whether the testing platform is reliable, whether embryo biopsy affects subsequent development, and whether prenatal diagnosis confirmation is needed after transfer. Some fertility centers in Kyrgyzstan use NGS (next-generation sequencing) platforms for PGT-M and PGT-A, aligning their technical approach with international standards. However, laboratory quality control, embryologist experience, and genetic counseling capabilities vary between centers. Doctors advise: before deciding to go to Kyrgyzstan, you must complete standard genetic counseling and genetic testing in China, obtain a clear genetic report, and then conduct a remote case evaluation with the fertility center in Kyrgyzstan to confirm they can design a testing protocol for your specific mutation site.
Easily Overlooked Details
| Overlooked Point | Specific Explanation | Consequence |
|---|---|---|
| Genetic report must include specific coordinates of the mutation site | PGT-M probe design requires knowledge of the gene's exon, intron regions, and the specific base mutation position. Simply stating "SMA carrier" is insufficient. | Unable to customize testing probe; cycle cancelled. |
| Both partners need to undergo carrier screening simultaneously | For recessive genetic diseases, it is necessary to confirm whether both are carriers; otherwise, PGT-M cannot block the disease. | The child may still be a carrier or affected after transfer. |
| Fertility centers in Kyrgyzstan need certification | Some centers claim to perform PGT but actually lack the capability for monogenic disease testing and can only do PGT-A (chromosome number screening). | The genetic disease is not blocked; the transfer still carries risk. |
| Cryopreservation and transport of embryos after biopsy | If Kyrgyzstan only performs the biopsy and testing is sent to a third-party laboratory, this involves embryo freezing and transport. | Risk of embryo loss during transport. |
| Prenatal diagnosis must be performed after transfer | PGT cannot 100% rule out misdiagnosis risk. Amniocentesis for verification is recommended after 16 weeks of pregnancy. | Missed detection could lead to the birth of a child with a genetic disease. |
Common Pitfalls to Avoid
- Blindly believing in "guaranteed success" promises: Any fertility center promising to "guarantee a healthy embryo" is unscientific. The normal embryo rate in PGT depends on the type of genetic disease and embryo quality. On average, only 1 to 3 out of every 5 to 8 embryos may be normal, and there is a risk of having no embryos for transfer.
- Starting the cycle without genetic counseling: Some couples, to save time, go directly to Kyrgyzstan with their genetic test reports but without standard genetic counseling. They do not understand the inheritance pattern, recurrence risk, or testing limitations, only to find out after starting the cycle that PGT-M is not suitable.
- Ignoring ovarian reserve assessment: When the woman is over 38 or has low AMH, the number of retrieved eggs is low, resulting in insufficient embryos. The probability of having no transferable embryos after PGT increases significantly. In such cases, consider egg donation or adjust the plan rather than blindly proceeding with a cycle.
- Choosing a center without PGT-M capability: Some fertility centers in Kyrgyzstan only perform PGT-A (chromosome aneuploidy screening) and cannot do PGT-M (monogenic disease). If the genetic disease is monogenic, PGT-A is meaningless.
- Ignoring legal and ethical differences: Kyrgyzstan's laws on embryo sex selection, embryo donation, and egg freezing differ from those in China. It is necessary to understand these in advance and confirm they align with your needs.
Specific Process: From Consultation to Transfer
- Genetic counseling and genetic testing in China: Complete pathogenic gene testing, chromosome karyotype analysis, and carrier screening at a正规 tertiary hospital's genetics or reproductive medicine department. Obtain a complete genetic report (including mutation site, inheritance pattern, and family verification results).
- Remote evaluation and protocol determination: Send all medical records (genetic report, AMH, semen analysis, woman's age, previous reproductive history) to the fertility center in Kyrgyzstan. A reproductive physician and geneticist will jointly assess suitability for PGT-M and provide an estimated normal embryo rate.
- Pre-cycle tests and document preparation: Complete infectious disease screening for both partners (HIV, hepatitis B, hepatitis C, syphilis), complete blood count, coagulation profile, liver and kidney function, thyroid function, cervical TCT, and semen culture. Passport must be valid for ≥18 months. Marriage certificate (some centers require notarized translation).
- Ovarian stimulation and egg retrieval: Start ovarian stimulation on day 2 of menstruation (average 10–12 days). Egg retrieval is performed under intravenous sedation, lasting 15–20 minutes. The male partner provides a semen sample after retrieval.
- Embryo culture and biopsy: Blastocysts form on days 5–6 after retrieval. The embryologist biopsies 5–8 cells from the trophectoderm of the blastocyst for PGT-M and PGT-A. The remaining blastocysts are cryopreserved.
- Genetic testing and embryo selection: The testing period typically takes 2–4 weeks. After results are available, normal embryos suitable for transfer are selected based on the presence of the pathogenic gene and chromosome copy number.
- Frozen-thawed embryo transfer: In the next cycle or a subsequent cycle, prepare the endometrium (natural or artificial cycle) and transfer 1–2 normal embryos. A pregnancy test is performed 12–14 days after transfer.
- Prenatal diagnosis confirmation: Ultrasound at 6–8 weeks after transfer confirms intrauterine pregnancy. After 16 weeks of pregnancy, amniocentesis is performed for genetic verification to confirm the fetal genetic status.
Timeline: How Long from Start to Transfer
| Stage | Time Required | Notes |
|---|---|---|
| Genetic counseling and genetic testing (in China) | 1–3 months | Some rare mutations require custom probes, which may take longer. |
| Remote evaluation and protocol determination | 1–2 weeks | Requires complete genetic report and reproductive test results. |
| Pre-cycle tests and document preparation | 2–4 weeks | Infectious disease screening, passport, notarization, etc. |
| Ovarian stimulation and egg retrieval | About 2 weeks | Includes waiting for menstrual cycle. |
| Embryo culture and biopsy | 5–10 days | From egg retrieval to completion of biopsy. |
| Genetic testing (PGT-M + PGT-A) | 2–4 weeks | Depends on testing platform and sample volume. |
| Frozen-thawed embryo transfer | 2–4 weeks | Must be completed within the endometrial preparation cycle. |
| Prenatal diagnosis confirmation | After 16 weeks of pregnancy | Not mandatory for the process, but strongly recommended. |
The total duration from starting genetic counseling to completing the transfer is generally 4–8 months. If genetic testing has already been completed, the cycle can be shortened to 3–5 months.
What Materials Are Needed
- Medical materials: Genetic test reports for both partners (in Chinese + English translation), chromosome karyotype analysis, AMH, sex hormone panel, semen analysis, infectious disease screening reports, and previous surgical records (if any history of uterine procedures).
- Identification materials: Passport (valid for ≥18 months), marriage certificate (some centers require notarization and translation into Russian or English), and household registration booklet (backup).
- Other: Genetic counseling records (proving full understanding of PGT limitations and risks), and previous reproductive history records (if there is a child with a genetic disease, provide diagnostic proof).
Handling Special Situations
Testing probe cannot be customized
For some rare or de novo mutations, the laboratory in Kyrgyzstan may not be able to design and validate the probe in the short term. In this case, a fallback option is to perform PGT-A (chromosome screening), but this cannot block monogenic genetic diseases. If the genetic disease is severe, transferring embryos without PGT-M is not recommended.
All embryos are abnormal
If all embryos carry the pathogenic gene or have chromosomal abnormalities, there are no transferable embryos. This is not uncommon in genetic carrier cycles, especially when the woman is over 37 or the man has high sperm DNA fragmentation. It is advisable to be mentally and financially prepared in advance and discuss contingency plans with the center (e.g., another stimulation cycle, considering embryo donation).
Miscarriage or pregnancy loss after transfer
PGT cannot prevent all miscarriages. Even with chromosomally normal embryos, maternal factors, immune factors, or endocrine factors can still lead to pregnancy failure. After a miscarriage, it is recommended to perform genetic re-testing of the embryo to confirm whether it was due to a testing error.
Frequently Asked Questions
Q: What is the approximate cost of third-generation IVF in Kyrgyzstan?
A: Depending on the chosen fertility center, whether third-party testing is needed, and whether embryo transport is involved, the total cost is approximately 80,000 to 150,000 RMB. This includes ovarian stimulation medication, egg retrieval surgery, embryo culture, biopsy, genetic testing, and frozen embryo transfer. The specific cost should be confirmed with the center based on the individual plan.
Q: How accurate is PGT testing in Kyrgyzstan?
A: The misdiagnosis rate for PGT-M is about 1%–2%, mainly due to allele drop-out (ADO) or contamination. Therefore, prenatal diagnosis after transfer is essential and cannot be replaced by PGT results.
Q: How many trips to Kyrgyzstan are required?
A: At least two trips. The first for the egg retrieval cycle (about 2 weeks), and the second for the transfer cycle (about 1–2 weeks). If using a frozen embryo transport model, you may only need to go once for egg retrieval and embryo culture, and the transfer can be done at a cooperating institution in China, but legality must be confirmed in advance.
Q: How to choose a fertility center in Kyrgyzstan?
A: Focus on three key points: whether they have an independent genetic laboratory or collaborate with certified genetic testing institutions; whether they have clinical cases of PGT-M and PGT-A; and whether they have genetic counselors to provide report interpretation. Do not only look at the cost; evaluate technical capability and quality control systems.
Risk Reminder
Genetic carriers choosing to go to Kyrgyzstan for third-generation IVF must clearly understand: PGT is not a panacea. It can only screen for known pathogenic genes and cannot eliminate all genetic risks. Embryo biopsy has a theoretical impact on embryo developmental potential, although current data suggest the impact is small. The error rate of testing platforms, while low, is not zero. Even after transferring a normal embryo, standard prenatal diagnosis is still required after pregnancy. Additionally, the medical dispute resolution mechanism in Kyrgyzstan differs from that in China. It is recommended to sign a clear informed consent form before starting the cycle, understanding clauses regarding embryo disposition, data confidentiality, and notification of abnormal results. It is not recommended to contact a center and start a cycle based solely on online information without completing standard genetic counseling. Every decision should be made after discussion with a genetic doctor and a reproductive physician.